ZIONEXA
Zionexa is an international and innovative company developing and commercializing in-vivo biomarkers for guiding targeted therapies in oncology, to improve patients’ pathway and provide them a better quality of life.
ZIONEXA
Industry:
Biotechnology
Founded:
2018-01-01
Address:
Fishers, Indiana, United States
Country:
United States
Website Url:
http://www.zionexa.com
Total Employee:
11+
Status:
Active
Contact:
1.844.946.6392
Total Funding:
5 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF WordPress LetsEncrypt SSL By Default Apache Microsoft Exchange Online Office 365 Mail Wordpress Plugins
Similar Organizations
Nivalis Therapeutics
Nivalis Therapeutics is a clinical-stage pharmaceutical company developing a novel class of disease modifying therapies.
NextVivo
NextVivo is a biotech company developing an immune organoid technology platform.
Investors List
IXO Private Equity
IXO Private Equity investment in Private Equity Round - Zionexa
Sofimac Innovation
Sofimac Innovation investment in Private Equity Round - Zionexa
Official Site Inspections
http://www.zionexa.com Semrush global rank: 13.98 M Semrush visits lastest month: 67
- Host name: 165.160.13.20
- IP address: 165.160.13.20
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Zionexa"
Zionexa - Crunchbase Company Profile & Funding
Organization. Zionexa . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Zionexa is an international and innovative company developing and commercializing in-vivo …See details»
GE Healthcare acquires Zionexa - 2021-05-06 - Crunchbase
May 7, 2021 Zionexa Zionexa is an international and innovative company developing and commercializing in-vivo biomarkers. Acquiring Organization: GE Healthcare GE Healthcare …See details»
GE Healthcare Acquires Zionexa; Molecular Imaging Agent Aims to …
May 6, 2021 GE Healthcare to scale Zionexa’s FDA-approved PET imaging agent, Cerianna (fluoroestradiol F-18), used as an adjunct to biopsy for the detection of estrogen receptor (ER) …See details»
Zionexa - Products, Competitors, Financials, Employees, …
Zionexa is an international company developing and commercializing molecular imaging solutions, companion diagnostics (CDx) for targeted therapies in oncology to improve patients' pathway …See details»
Zionexa Company Profile 2024: Valuation, Investors, Acquisition
Zionexa General Information Description. Developer of molecular imaging technology designed to diagnose metastatic breast cancer. The company's technology provides physicians with new …See details»
Zionexa - Funding, Financials, Valuation & Investors - Crunchbase
Zionexa is an international and innovative company developing and commercializing in-vivo biomarkers. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. ... How much …See details»
GE Healthcare Acquires Zionexa to Enable More Targeted …
May 6, 2021 The company aims to develop and bring to market Zionexa’s pipeline biomarkers, as well as the recently FDA-approved PET imaging agent, Ceriannaâ„¢ (fluoroestradiol F-18), …See details»
GE Healthcare acquires Zionexa and its FDA-approved PET …
GE Healthcare announced the acquisition of Zionexa, a leading innovator of in-vivo oncology and neurology biomarkers that help enable more personalized healthcare. The company aims to …See details»
Zionexa SAS - Drug pipelines, Patents, Clinical trials - Synapse
Explore Zionexa SAS with its drug pipeline, therapeutic area, technology platform, 4 clinical trials, 7 news, Disease Domain:Neoplasms, Technology Platform:Small molecule drug, Diagnostic …See details»
GE Healthcare Acquires Zionexa; Molecular Imaging Agent Aims to …
May 7, 2021 Marlborough, MA, U.S. – 6 May 2021 – GE Healthcare today announced the acquisition of Zionexa, a leading innovator of in-vivo oncology and neurology biomarkers that …See details»
Zionexa US Corporation Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Zionexa US Corporation of Marlborough, MA. Get the latest business insights from Dun & Bradstreet.See details»
GE Healthcare Acquires Zionexa; Molecular Imaging Agent Aims to …
May 6, 2021 GE Healthcare to scale Zionexa’s FDA-approved PET imaging agent, Cerianna (fluoroestradiol F-18), used as an adjunct to biopsy for the detection of estrogen receptor (ER) …See details»
GE Healthcare Acquires Zionexa - Goodwin Procter
May 11, 2021 Founded in 2018, Zionexa develops and commercializes molecular imaging solutions for targeted therapies in oncology to improve therapeutic management in the …See details»
GE Healthcare Acquires Zionexa; Molecular Imaging Agent Aims to …
May 6, 2021 Zionexa is an international and innovative company developing and commercializing in-vivo biomarkers for guiding targeted therapies in oncology, to improve …See details»
GE Healthcare acquires oncology biomarker maker Zionexa
May 7, 2021 GE Healthcare pharmaceutical diagnostics president and CEO Kevin O’Neill said: “Like GE Healthcare, Zionexa’s products are aimed at enabling more precise diagnosis, …See details»
GE Healthcare : Acquires Zionexa; Molecular Imaging Agent Aims …
May 6, 2021 GE Healthcare to scale Zionexa’s FDA-approved PET imaging agent, Cerianna (fluoroestradiol F-18), used as an adjunct to biopsy for the detection of estrogen receptor (ER) …See details»
GE Healthcare Acquires Zionexa and its Metastatic Breast Cancer …
6 days ago GE Healthcare acquired Zionexa, an in-vivo oncology and neurology biomarker company that received US FDA-clearance in May 2020 for Cerianna, a PET imaging agent …See details»
GE Healthcare picks up ER-positive breast cancer imaging agent in ...
May 6, 2021 RELATED: GE Healthcare rolls out new AI-powered chest X-ray suite The financial terms of the acquisition were not disclosed, but all two dozen of Zionexa’s employees are …See details»
GE Healthcare Acquires Zionexa; Molecular Imaging Agent Aims
May 6, 2021 GE Healthcare today announced the acquisition of Zionexa, a leading innovator of in-vivo oncology and neurology biomarkers that help enable more personalized healthcare. …See details»
GE Healthcare Acquires Zionexa; Molecular Imaging Agent Aims to …
May 6, 2021 GE Healthcare to scale Zionexa’s FDA-approved PET imaging agent, Cerianna (fluoroestradiol F-18), used as an adjunct to biopsy for the detection of estrogen receptor (ER) …See details»